Skip to main content
. 2024 Feb 15;13(2):465–473. doi: 10.1007/s40120-024-00586-w

Table 3.

Patients’ switching patterns

CGRP mAbs switching profile Gepants switching profile
Patient 1 Erenumab to eptinezumab Rimegepant to ubrogepant
Patient 2 Galcanezumab to eptinezumab Rimegepant to ubrogepant
Patient 3 Erenumab to eptinezumab Rimegepant to ubrogepant
Patient 4 Erenumab to eptinezumab Rimegepant to ubrogepant
Patient 5 Eptinezumab to erenumab Rimegepant to ubrogepant